MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Celgene (NASDAQ: CELG)
Finance & Acquisitions: Celgene
Acetylon Pharmaceuticals
Finance & Acquisitions: Acetylon
Parents
Acetylon Pharmaceuticals
Children
2011: Acetylon Pharmaceuticals Announces Completion of $27 Million Series B Round of Private Investor Financing (2011)
2011: Acetylon Pharmaceuticals Raises $27 Million Series B to Push HDAC Inhibitor into Phase I/II Cancer Trials (2011)
2011: Acetylon Pharmaceuticals, Inc.: Series B $12.4M (2011)
2011: Backed by Eclectic Financiers, Acetylon Begins Trials of Cancer Drug (2011)
2012: Celgene Pours $15M Into Acetylon, Takes “Observer” Role on Board (2012)
2017: Celgene Looks Cheap Right Now - Celgene Corporation (NASDAQ:CELG)
Participants include NewSpring Health Capital and others.
The proceeds will be used in part to fund the advancement of the Company’s lead drug candidate ACY-1215 – a next-generation Class II-selective histone deacetylase (HDAC) inhibitor – into Phase I/II clinical testing for patients with relapsed and relapsed-r
The Series B funding complements $4.9 million in funding from The Leukemia & Lymphoma Society
Jumps
*Key People: Acetlyon
Organization & Developments: Acetylon